Early trial tests new combo for tough blood cancers
NCT ID NCT02328014
Summary
This study tested a new combination of two drugs, acalabrutinib and ACP-319, for people with B-cell cancers like non-Hodgkin's lymphoma and multiple myeloma. The main goals were to find the safest dose and see if the treatment was effective at controlling the disease. It involved 40 participants and was an early-phase trial focused on safety and initial results.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Orange, California, 92868, United States
-
Research Site
Bethesda, Maryland, 20892, United States
-
Research Site
Rochester, New York, 14642, United States
-
Research Site
Portland, Oregon, 97239, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Austin, Texas, 78705, United States
-
Research Site
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.